Ate-Bev Early Response Prediction Model in Advanced HCC

Seoul National University

Status: Enrolling

Conditions: Atezolizumab-bevacizumab; Hepatocellular Carcinoma; Response Evaluation

Treatments: Diagnostic Test: Early response evaluation

Study type: Observational

Funder types: Other

Identifiers

NCT05763277

2206-066-1332

Details and patient eligibility

About

The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. Therefore, this study aimed to create a predictive model that can detect treatment response at an early stage.

Enrollment: 170 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients who were diagnosed with advanced hepatocellular carcinoma and who were scheduled to receive atezolizumab-bevacizumab as the first-line therapy
• Patients willing to participate in this study

Exclusion criteria

• Individuals with a history of severe contrast allergy
• Individuals with severe comorbidities (according to the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction.)

Trial design

170 participants in 1 patient group

Ate-Bev

Description:

Individuals diagnosed with advanced hepatocellular carcinoma and treated with atezolizumab-bevacizumab between the ages of 18-80 were included. According to the recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, patients with comorbidities were excluded.

Treatment:

Diagnostic Test: Early response evaluation